Romidepsin (FK228, Depsipeptide)

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26062.00
JPY 79182.00
JPY 115702.00

カスタマーフィードバック(4)

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NV\pb49iS2WubDDWbYFjcWyrdImgRZN{[Xl? M1yzTlIvPS1zNTDuUS=> MXW3NkBp NUL6ZYhIcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NUjjZZpTOjV5OUC5NFc>
U2932  MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH7hOZIzNjVvMUWgcm0> MnHuO|IhcA>? MkfrbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? Mn[zNlU4QTB7MEe=
OCI-LY7 M1\L[WNmdGxiVnnhZoltcXS7IFHzd4F6 MVSyMlUuOTVibl2= NHHCcWc4OiCq MXvpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NXLWWYVEOjV5OUC5NFc>
Farage NYrDVo45S2WubDDWbYFjcWyrdImgRZN{[Xl? NE\X[HUzNjVvMUWgcm0> M2f1fFczKGh? NI\HdphqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NWq0PWs5OjV5OUC5NFc>
LY7/EBV MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIPuW2MzNjVvMUWgcm0> NETjb3M4OiCq NGXPRphqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NVKyTmN[OjV5OUC5NFc>
U2932/EBV NHKzRY9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWny[pl4Oi53LUG1JI5O NF7Pe4U4OiCq NE\4V5dqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NH3ycZgzPTd7MEmwOy=>
HCT116 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe1MVUxODBibl2= NXPPSJBrOjRiaB?= MXHEUXNQ NWjNV2FmcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MkXtNlU1QTJ3MUW=
ACH-2 MlnMSpVv[3Srb36gRZN{[Xl? NYD2UYV3OS17IH7N NEf6W|UzPCCq MmHNbY5lfWOnczDITXYuOSCHbo[g[ZhxemW|c3nvci=> M4f2U|I2OTR7NE[3
MCF-10A MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3lVGVsUUN3ME2wMlE4yrFyLkCxJI5O MmXVNlQ6PTR6NU[=
MCF-7 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwMUFCtVAvOjBibl2= MWCyOFk2PDh3Nh?=
SK-BR-3 NGX0SW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T6fGlEPTB;MT6wNOKyOC5|NTDuUS=> MX[yOFk2PDh3Nh?=
MDA-MB-231 M4HaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TmdmlEPTB;MD62POKyOC5zNDDuUS=> NYPmXGNSOjR7NUS4OVY>
PC3 M4PF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITsTHRKSzVyPUGuOlXDuTBwM{Wgcm0> NEP6VI4zPDl3NEi1Oi=>
HCT116 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwMEFCtVAvODBibl2= NFTYcHMzPDl3NEi1Oi=>
HCT116-p21-/- MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMkdCtVAvOzdibl2= NGfnW3UzPDl3NEi1Oi=>
S1 M3ToVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fF[WlEPTB;Nz62O:KyOC5{OTDuUS=> NWG4Vpl1OjR7NUS4OVY>
SW620 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmyTWM2OD1yLkmzxtExNjJ7IH7N MnHjNlQ6PTR6NU[=
LOX-IMVI MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi5TWM2OD1yLki3xtExNjB|IH7N M2TQflI1QTV2OEW2
UACC-62 NEixcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzOTWM2OD1yLkW2xtExNjF4IH7N M1rUdFI1QTV2OEW2
MDA-MB-435 NUe5NYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHQTWM2OD1yLkmwxtExNjB4IH7N NYD2OVFmOjR7NUS4OVY>
SF-295 NHfSd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwOElCtVAvOTVibl2= M{LwOlI1QTV2OEW2
A549 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XVNWlEPTB;MT6yOuKyOC5{NDDuUS=> M2\3TVI1QTV2OEW2
H460 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TqZmlEPTB;Mj61POKyOC56MDDuUS=> MXGyOFk2PDh3Nh?=
EKVX MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\yTWM2OD1zLkOzxtExNjN2IH7N MWqyOFk2PDh3Nh?=
H146 NGTHd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPU[FNQUUN3ME2wMlIzyrFyLkC3JI5O MYGyOFk2PDh3Nh?=
H526 NFXaeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1TWM2OD1yLkG1xtExNjB|IH7N MlHQNlQ6PTR6NU[=
HuT-78 NF74ellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLPNINKUUN3ME2xMlc{yrFyLkS0JI5O NV3Jd5dYOjR7NUS4OVY>
HA NVzqbpNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnXNE43OjVvMUDuUS=> M1uy[VQ5KGh? NUD1c3pGcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? NEjtTGMzPDd5MUWxNC=>
MS-275 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33IcFAvPjJ3LUGwcm0> MWm0PEBp M1PBVolv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj NGHteYYzPDd5MUWxNC=>
CD4 T Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\qW5U1QCCq MojmSWM2OD12LkZCtVEvOCCwTR?= NHXGfpMzPDd{MkS1OC=>
CD4 T NHjvV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;YOFghcA>? MWDDR|UxRTFyN9MxNVI3KG6P NFfOW3gzPDd{MkS1OC=>
CD4+ T NGCwTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7YRXZXTUN3ME2zJI5O MYmyOFQ6PTFyNR?=
A549 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;USFEx6oDVMUCwxsBvVQ>? MlrKNlQwOzZxNEigbC=> MlPvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M4iyelI1PDh3N{m5
JJN3 M1flRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXZXIFuOjRxNEigbC=> NU\q[npSTUN3MEyx5qCKdk19IES45qCKcA>? MnTINlQxOzBzNUC=
OPM-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXlNlQwPDhiaB?= MXHFR|Uxez1z4pEJcm08KDR64pEJbC=> M3jDNVI1ODNyMUWw
RPMI-8226 MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TNSlI1NzR6IHi= MVLFR|Uxez1zLklihKlvVTtiNElihKlp MnTJNlQxOzBzNUC=
U266 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjBOnZUOjRxNEigbC=> MlfpSWM2OHN;MUFihKlvVTtiNElihKlp NYHyXIczOjRyM{CxOVA>
CA46 Mm\xRZBweHSxc3nzJGF{e2G7 NWXVfW1TPiCq MXTpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MV6yN|k3PjF4NB?=
DG75 NVnmc3NkSXCxcITvd4l{KEG|c3H5 NYDSRmVOPiCq NILsNm1qdmS3Y3XzJI5wKGGyb4D0c5Nqew>? NGiwWZQzOzl4NkG2OC=>
Ramos NWfETYZHSXCxcITvd4l{KEG|c3H5 M3jFcFYhcA>? MYfpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= NUfsTHFvOjN7Nk[xOlQ>
ST486 M1nNe2Fxd3C2b4Ppd{BCe3OjeR?= MnyzOkBp MlnpbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz NYj5b5NiOjN7Nk[xOlQ>
HuT78 MlvKRZBweHSxc3nzJGF{e2G7 NX;NbXRvOS9zMD:xNFAhdk1? NF;5cVY1QCCq NFz0Z|BqdmS3Y3XzJIFxd3C2b4Ppd{BifCBzIH7N M1\2RVI{PTN{N{Oy
DpVp35 M3TuOGFxd3C2b4Ppd{BCe3OjeR?= MXixM|ExNzFyMDDuUS=> NVv6NZo5PDhiaB?= NUnKPIhCcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NWPvZYxuOjN3M{K3N|I>
DpVp50 NUHEbVcySXCxcITvd4l{KEG|c3H5 Mn7CNU8yOC9zMECgcm0> NEn0dZo1QCCq MljabY5lfWOnczDicJVvfCCjcH;weI9{cXN? M4DX[|I{PTN{N{Oy
DpP75  M1POT2Fxd3C2b4Ppd{BCe3OjeR?= MmD1NU8yOC9zMECgcm0> MV[0PEBp NULzdolHcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MV2yN|U{Ojd|Mh?=
SKOV-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W0V|HjiJN{MH7N M{fuUVczKGh? NXzTOVU4TE2VTx?= NH\BWpNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NFLEbpIzOzBzMEO0PC=>
Brca1 WT MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\SblHjiJN{MH7N NE\ROZE4OiCq M3nqUmROW09? MXzy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NHzwXWczOzBzMEO0PC=>
Brca1 Null M3\mZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXEbZYy6oDVMkDuUS=> MYG3NkBp NFjLOGRFVVOR NYLWV5NQemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MojHNlMxOTB|NEi=
OVCAR-8  NIftPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\2NVHjiJN{MH7N MVG3NkBp MknISG1UVw>? MWHy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> M3zUXVI{ODFyM{S4
NCI/ADR-RES NXrlVXhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGx5qCUOjCwTR?= M3;ZOFczKGh? MYXEUXNQ NWDjNJFRemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NUjON5d3OjNyMUCzOFg>
HCT116 M3;TVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\YOUBvVS13MDFOwG0> MX2yOEBp MkDiSG1UVw>? MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NWDtenpPOjJ7MkS5OVg>
RKO NGfTUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnjbGc2KG6PLUWwJO69VQ>? MVKyOEBp NH7RSldFVVOR NFz0eJFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M2XHUFIzQTJ2OUW4
CO115 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7Se3ZRPSCwTT21NEDPxE1? NFS0fpYzPCCq MmX0SG1UVw>? M3\4N4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MUSyNlkzPDl3OB?=
HFS NEfuUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzUblFzPSCwTR?= MYqyOE81QC95MjDo M33ERYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> MWiyNlExPjJ6Mh?=
LNCaP NXLCdm5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPhfoI2KG6P M1PFdlI1NzR6L{eyJIg> MmDhbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MXqyNlExPjJ6Mh?=
A549 NE[wW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjhPHo2KG6P MlLTNlQwPDhxN{KgbC=> NFHifmpqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 M1X4ZlIzOTB4Mkiy
697  NYGzdWZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W1WGlEPTEkgJm95qCKOi53wrDuUS=> MYWyNVU{QDJzNh?=
697-R MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\3TWM2OOLCiU5ihKk5NjcEoH7NxsA> Mo\MNlE2Ozh{MU[=
HUT78 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFibl2= M2HXWFIyOTl6NUS1
THJ-16T NGTFO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfvT4NnOSCwTR?= NHrnWFEzPCCq M3HWTYlvcGmkaYTzJINmdGxiZ4Lve5Rp NYi5bHBROjB6MUC1Olg>
HCT116 NFixS2FHfW6ldHnvckBCe3OjeR?= NVvPfJVTOjBibl2= MluyPEBp Mnm5cY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w NUjxUlJYOjB5M{m0OVQ>
B104  NYnzR|NkTnWwY4Tpc44hSXO|YYm= M1vrTVIhdk1? MXGyOE81QC95MjDo M4f6dolv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?= MYmyNFY5PjVyNR?=
HL-60  MoLpR5l1d3SxeHnjbZR6KEG|c3H5 M3rEXlEuPTByIH7N M4TBd|I1KGh? MknqbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MkTyNlA3OjRzNkO=
HP100 NUDVXZl7S3m2b4TvfIlkcXS7IFHzd4F6 M1zOelEuPTByIH7N NWDxfIJwOjRiaB?= MmHTbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M1jqc|IxPjJ2MU[z
HL-60  NEO0fFJHfW6ldHnvckBCe3OjeR?= MXGxNEBvVQ>? NIjIfnc1NzZxMU[gbC=> M1XKSIlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= NXjlPHVKOjB4MkSxOlM>
HP100 M4jaNGZ2dmO2aX;uJGF{e2G7 NF;kUZMyOCCwTR?= M{jSW|QwPi9zNjDo NUnVV4lYcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo MnXnNlA3OjRzNkO=
HL-60  MmXSSpVv[3Srb36gRZN{[Xl? MWGxNE02ODBibl2= MXq0JIg> M1;IOYRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= MXSyNFYzPDF4Mx?=
HP100 MnHBSpVv[3Srb36gRZN{[Xl? M3W4V|ExNTVyMDDuUS=> MmDCOEBp NUO3dlNb\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg NG\OUo0zODZ{NEG2Ny=>
11z MWLLbY5ie2ViQYPzZZk> M3W3OlMuOTByIH7N NV3UbXJ1emWmdXPld{BJTEGFIHXufplu[XSrYzDhZ5Rqfmm2eTCoTWM2OMLiPTC2MlUhyrFiMD62JI5ud2xxTDm= M4\NW|IxPjB3MUS0
SKOV-3 M3LLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PkPVQwQC9zNjDuUS=> M{XWOlQ5KGh? MlHYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MmDxNlA1ODR3NkS=
OVCAR-3 NF3T[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z1e|QwQC9zNjDuUS=> MnuwOFghcA>? NIDVboJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NVXmRYh1OjB2MES1OlQ>
HBL-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTaUVMzNTFyIH7N M1\QTlI1KGh? NV7PRYl4UUN3ME20MlMhdk1? M1fCVVIxODZ6MEiw
Jeko-1 NXHhO41yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nQdlIuPTBibl2= Mk\ONlQhcA>? MXHJR|UxRTFzIH7N MUmyNFA3QDB6MB?=
Granta-519 M3uw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz6N291PS12MDDuUS=> M2XZVVI1KGh? NIrRemtKSzVyPUW4MlUhdk1? NFO4TmozODB4OEC4NC=>
L1236 M1H5PGN6fG:2b4jpZ4l1gSCDc4PhfS=> NXGweZZGOSCwTT2xNFAh|ryP MkfhOFghcA>? MYfFR|UxRTBwMEeg{txO NVjpZYdPOTl{M{O0O|A>
L428 MV3DfZRwfG:6aXPpeJkhSXO|YYm= M4GzOFEhdk1vMUCwJO69VQ>? NGfBU|U1QCCq NEfXXplGSzVyPUCuOFMh|ryP NHn3XmkyQTJ|M{S3NC=>
KM-H2 NFe5NZJEgXSxdH;4bYNqfHliQYPzZZk> MX6xJI5ONTFyMDFOwG0> NFzT[m41QCCq M4LtfmVEPTB;MD61PEDPxE1? M1HTe|E6OjN|NEew
L540Cy NHvRVVFEgXSxdH;4bYNqfHliQYPzZZk> M3fQZlEhdk1vMUCwJO69VQ>? NIfWV3M1QCCq M4HzV2VEPTB;MD6xOkDPxE1? M1W2dVE6OjN|NEew
G401 M2LHc2Z2dmO2aX;uJGF{e2G7 NWiyNVExOTBibl2= M3joOFI1NzR6L{eyJIg> MWjEUXNQ NYLEelR6cW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NFrIcJIyQTJ{MUW4Oi=>
STM91-01 NYXaPIVGTnWwY4Tpc44hSXO|YYm= MoXNNVAhdk1? M2rESVI1NzR6L{eyJIg> M3LkeGROW09? MXrpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MVSxPVIzOTV6Nh?=
SJSC  MlfQSpVv[3Srb36gRZN{[Xl? NF7DOVMyOCCwTR?= MXyyOE81QC95MjDo MYfEUXNQ MYXpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NF7zXmMyQTJ{MUW4Oi=>
BT16  MW\GeY5kfGmxbjDBd5NigQ>? NWHUNINSOTBibl2= NHfYbWczPC92OD:3NkBp Mmm3SG1UVw>? MULpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MYSxPVIzOTV6Nh?=
NCI-H1299 NHjDe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXMbHhLUUN3ME20MlbDuTBwMjDu[{9udA>? MnW5NVkyPzl6OUC=
NCI-2882 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO2W2pPUUN3ME2xMlbDuTBwMESgcocwdWx? M3:0V|E6OTd7OEmw
HCC95 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\0TWM2OD1{LkZCtVAvODVibnevcYw> NUjm[4s3OTlzN{m4PVA>
NCI-H23 NUH2UnNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fNOGlEPTB;Mj65xtExNjJibnevcYw> MVyxPVE4QTh7MB?=
NCI-H157 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHhTWM2OD1zLkdCtVAvODJibnevcYw> MnHyNVkyPzl6OUC=
NCI-H460 NWe4UIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJwMdMxNE4xPyCwZz;tcC=> M3v1PFE6OTd7OEmw
NCI-H1975 M2HzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nKdmlEPTB;MT6zxtExNjB2IH7nM41t NFHPRW8yQTF5OUi5NC=>
NCI-H820 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH2WYZKSzVyPUKuOOKyOC5zIH7nM41t M{HOSVE6OTd7OEmw
NCI-H1650 NFjqT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW3S4NKSzVyPUSuPeKyOC5|IH7nM41t Ml7QNVkyPzl6OUC=
DTC1 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjoSoVtUUN3ME2wMlUyKG6P MoK2NVg2PjZ{NE[=
KAO M2TJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHSTWM2OD1yLkmxJI5O NH\tR4syQDV4NkK0Oi=>
SU-CCS-1 NUH3SnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nucmlEPTB;MD64PUBvVQ>? NGHqOpgyQDV4NkK0Oi=>
SYO-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\TV2lEPTB;MD62O{BvVQ>? NUDGPGhqOTh3Nk[yOFY>
FUJI NEnu[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\wV3ZKSzVyPUGuN|Ehdk1? M3XmWFE5PTZ4MkS2
SKNMC NW\hPZgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\4OWlEPTB;MT6xO{BvVQ>? MnrZNVg2PjZ{NE[=
402-91 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMk[gcm0> NWTWcnpVOTh3Nk[yOFY>
1765-92 M3fyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fXN2lEPTB;MT63O{BvVQ>? Mn:xNVg2PjZ{NE[=
JN-DSRCT-1 NH\ENlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwMkWgcm0> NFrjPFcyQDV4NkK0Oi=>
NMS-2PC MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwOEGgcm0> NWHXR|FuOTh3Nk[yOFY>
HL60 NEGxR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX6ybIEyUUN3ME2xMlg3KG6P M3;3SFE5PTZ4MkS2
A549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLCZ5BYUUN3ME2zMlI1KG6P NWjEXYRMOTh3Nk[yOFY>
SW480 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHVUYVkUUN3ME2yMlY6KG6P NVTxRoNHOTh3Nk[yOFY>
MCF7 M2HWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi4WVZKSzVyPUOuOVUhdk1? MWSxPFU3PjJ2Nh?=
PC-3 M2D5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jEe2lEPTB;Mj61NUBvVQ>? MW[xPFU3PjJ2Nh?=
MMRU MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2TWM2OD1{LkW3JI5O Moe4NVg2PjZ{NE[=
Hs68 NEHxR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRT5zMDDuUS=> MVqxPFU3PjJ2Nh?=
hMSC-001F NFm1c3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHuSWtKSzVyPU6xNEBvVQ>? M4XJdlE5PTZ4MkS2

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID